SG11201808322PA - Carboxylic acid for treating/preventing nasal congestion - Google Patents
Carboxylic acid for treating/preventing nasal congestionInfo
- Publication number
- SG11201808322PA SG11201808322PA SG11201808322PA SG11201808322PA SG11201808322PA SG 11201808322P A SG11201808322P A SG 11201808322PA SG 11201808322P A SG11201808322P A SG 11201808322PA SG 11201808322P A SG11201808322P A SG 11201808322PA SG 11201808322P A SG11201808322P A SG 11201808322PA
- Authority
- SG
- Singapore
- Prior art keywords
- carboxylic acid
- international
- nasal congestion
- treating
- acceptable salt
- Prior art date
Links
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title abstract 7
- 206010028735 Nasal congestion Diseases 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 abstract 5
- 206010061218 Inflammation Diseases 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 230000004054 inflammatory process Effects 0.000 abstract 3
- 102220240796 rs553605556 Human genes 0.000 abstract 3
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 210000002345 respiratory system Anatomy 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16169882 | 2016-05-17 | ||
| PCT/EP2017/061832 WO2017198702A1 (en) | 2016-05-17 | 2017-05-17 | Carboxylic acid for treating/preventing nasal congestion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808322PA true SG11201808322PA (en) | 2018-10-30 |
Family
ID=56014856
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808322PA SG11201808322PA (en) | 2016-05-17 | 2017-05-17 | Carboxylic acid for treating/preventing nasal congestion |
| SG10202006016QA SG10202006016QA (en) | 2016-05-17 | 2017-05-17 | Carboxylic acid for treating/preventing nasal congestion |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202006016QA SG10202006016QA (en) | 2016-05-17 | 2017-05-17 | Carboxylic acid for treating/preventing nasal congestion |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200000751A1 (enExample) |
| EP (1) | EP3458043A1 (enExample) |
| JP (1) | JP6975473B2 (enExample) |
| KR (1) | KR102430892B1 (enExample) |
| CN (1) | CN109152754A (enExample) |
| AU (1) | AU2017266726A1 (enExample) |
| BR (1) | BR112018072177A2 (enExample) |
| CA (1) | CA3020485A1 (enExample) |
| CL (1) | CL2018003270A1 (enExample) |
| MX (1) | MX2018013475A (enExample) |
| RU (1) | RU2018143564A (enExample) |
| SG (2) | SG11201808322PA (enExample) |
| WO (1) | WO2017198702A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11948678B2 (en) * | 2009-10-14 | 2024-04-02 | Trice Imaging, Inc. | Systems and devices for encrypting, converting and interacting with medical images |
| US11206245B2 (en) * | 2009-10-14 | 2021-12-21 | Trice Imaging, Inc. | Systems and devices for encrypting, converting and interacting with medical images |
| GB202004690D0 (en) * | 2020-03-31 | 2020-05-13 | Edinburgh Napier Univ | Composition for enhancing immune response of cells |
| US12414928B2 (en) | 2021-05-14 | 2025-09-16 | Rene Dumalaog Javier | Viral inactivation spray and gargling formulation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6063363A (en) * | 1997-05-27 | 2000-05-16 | Goodwin; Gary J | Treatment for upper respiratory tract infections with potassium salts |
| HUP0101369A3 (en) * | 1997-12-23 | 2002-11-28 | Schering Corp | Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine |
| US8912174B2 (en) * | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
| DE10337186A1 (de) * | 2003-08-13 | 2005-03-17 | Merck Patent Gmbh | Wässrige Wirkstoff-Lösung |
| EP1671629A4 (en) * | 2003-09-19 | 2008-11-26 | Otsuka Pharma Co Ltd | HUMAN BETA DEFENSIN SECRETION AMPLIFIER |
| US20070256812A1 (en) * | 2006-04-19 | 2007-11-08 | Wen-Chen Wei | Multidirectional heat dissipating structure |
| US20070286812A1 (en) * | 2006-06-09 | 2007-12-13 | Toutounghi Camille | Nasal formulation |
| US9415033B2 (en) * | 2012-10-03 | 2016-08-16 | Proponent Biotech Gmbh | Esters of short chains fatty acids for use in the treatment of immunogenic disorders |
-
2017
- 2017-05-17 CA CA3020485A patent/CA3020485A1/en not_active Abandoned
- 2017-05-17 US US16/097,784 patent/US20200000751A1/en not_active Abandoned
- 2017-05-17 EP EP17723139.6A patent/EP3458043A1/en not_active Withdrawn
- 2017-05-17 JP JP2019513481A patent/JP6975473B2/ja active Active
- 2017-05-17 SG SG11201808322PA patent/SG11201808322PA/en unknown
- 2017-05-17 CN CN201780029992.2A patent/CN109152754A/zh active Pending
- 2017-05-17 RU RU2018143564A patent/RU2018143564A/ru unknown
- 2017-05-17 KR KR1020187033155A patent/KR102430892B1/ko active Active
- 2017-05-17 MX MX2018013475A patent/MX2018013475A/es unknown
- 2017-05-17 BR BR112018072177-8A patent/BR112018072177A2/pt not_active IP Right Cessation
- 2017-05-17 WO PCT/EP2017/061832 patent/WO2017198702A1/en not_active Ceased
- 2017-05-17 AU AU2017266726A patent/AU2017266726A1/en not_active Abandoned
- 2017-05-17 SG SG10202006016QA patent/SG10202006016QA/en unknown
-
2018
- 2018-11-16 CL CL2018003270A patent/CL2018003270A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017266726A1 (en) | 2018-10-11 |
| JP6975473B2 (ja) | 2021-12-01 |
| WO2017198702A1 (en) | 2017-11-23 |
| JP2019516797A (ja) | 2019-06-20 |
| KR102430892B1 (ko) | 2022-08-09 |
| KR20190009294A (ko) | 2019-01-28 |
| CA3020485A1 (en) | 2017-11-23 |
| US20200000751A1 (en) | 2020-01-02 |
| CN109152754A (zh) | 2019-01-04 |
| MX2018013475A (es) | 2019-08-12 |
| SG10202006016QA (en) | 2020-07-29 |
| RU2018143564A3 (enExample) | 2020-07-23 |
| BR112018072177A2 (pt) | 2019-02-12 |
| EP3458043A1 (en) | 2019-03-27 |
| CL2018003270A1 (es) | 2019-02-22 |
| RU2018143564A (ru) | 2020-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201811580SA (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201811209QA (en) | Oral gastroretentive formulations and uses thereof | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201407110QA (en) | Novel dosage form and formulation of abediterol | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201809100QA (en) | Use of gram negative species to treat atopic dermatitis | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201804057TA (en) | An actuator housing for a metered dose inhaler device | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201907159SA (en) | Treatment of hidradenitis suppurativa | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases |